NuLifeBotics has developed an innovative AI-powered sperm analysis platform integrated with deep learning to improve the evaluation of sperm morphology, motility, and DFI. With an array of user-friendly features, the company’s software enables the selection of healthy sperm samples through still photos and live videos, efficiently detect abnormalities through advanced CNN models, and precisely track sperm movement to assess motility. Moreover, it has offered a comprehensive analysis of sperm images and videos for DNA fragmentation, all geared towards enhancing the accuracy of fertility treatments and increasing the likelihood of successful pregnancies. From predictive personalization to offering invaluable suggestions, the company’s software has streamlined processes and facilitated real-time data analysis, shaping the future of reproductive healthcare.
To redefine reproductive health with cutting-edge AI technology, empowering individuals with precise, accessible, and proactive fertility solutions.
To provide embryologists and fertility clinics with a powerful tool that uses AI technology to enhance sperm selection and analysis.
In vitro fertilization (IVF) is a widely used fertility treatment, but its success rate remains modest at around 30% per cycle. One of the key factors contributing to this challenge is the selection of optimal sperm for fertilization.
The process of manual sperm selection is plagued by several challenges. It's not only time-consuming, with embryologists spending approximately 2.5 hours assessing sperm samples at 100× magnification, but it's also highly subjective.
Traditional semen analysis offer valuable information but often fail to provide a comprehensive assessment of sperm quality. Parameters such as sperm morphology, DNA fragmentation, and motility.
Sperm morphology, which refers to the size and shape of sperm, is a crucial factor in male infertility. However, manual assessment of sperm morphology by embryologists can be inconsistent. It is time consuming.
NuLifeBotics has developed an AI-powered sperm analysis platform to address the limited success rate in IVF by significantly improving the selection of sperm samples. It has made use of advanced algorithms and deep learning to assess sperm morphology, motility, and DNA integrity with precision. By identifying and selecting the healthiest sperm, the platform enhances the chances of successful fertilization. This has resulted in a higher success rate for IVF cycles, providing couples with a more effective path to parenthood.
The Company's AI platform has solved the issues associated with time-consuming and subjective sperm selection by automating the process. Using deep learning and CNN models, it has rapidly and objectively identified the most suitable sperm in a sample. This automation has reduced the time required for sperm selection and eliminated the subjectivity associated with manual assessment. The result is a more efficient, consistent, and cost-effective approach to choosing sperm for fertility treatments.
The Company's AI platform has offered a comprehensive evaluation of sperm quality to address the limitations of traditional semen analysis. It has delved into multiple parameters, including morphology, DNA fragmentation, and motility. This in-depth analysis has offered fertility specialists a holistic understanding of the sperm's fertilization potential. This wealth of data has enabled specialists to tailor treatment plans more effectively, addressing specific issues and increasing the chances of a successful pregnancy.
The AI platform has addressed the inconsistencies in manual sperm morphology assessment by delivering a quick evaluation. It has leveraged advanced image analysis and machine learning to assess sperm morphology within seconds, ensuring a reliable and repeatable process. By offering a faster and more dependable assessment of sperm morphology, the platform has contributed to more accurate diagnoses and treatment outcomes, reducing the risk of misinterpretation and improving the overall effectiveness of fertility treatments.
Mrs. Huynh Nhu Giang, a seasoned senior specialist in In Vitro Fertilization (IVF) with over 18 years of expertise in Assisted Reproductive Technology (ART) and IVF, is adept at leading, managing, and researching fertility treatment and reproductive healthcare. She has worked in various roles such as IVF specialist, Deputy Head/IVF specialist, and Head of Reproductive Support Department. As Chief Executive Officer of NuLifeBotics, Mrs. Huynh Nhu Giang focuses on advancing technologies, conducting market research, and fostering strategic partnerships to ensure the company’s success in the Canadian market.
Mrs. Thi Quynh Huong Do is a results-driven and accomplished senior director with over 27 years of experience in healthcare management and public health. Proficient in strategic planning, policy development, and implementation, she has held various roles such as Labor Contract Officer, Specialist in the national committee for population and family planning, Specialist in the committee on population, family, and children, Specialist in the General Department of Population and Family Planning, and Deputy Director in the Department of Population Structure and Quality. As Chief Operating Officer of NuLifeBotics, Mrs. Thi Quynh Huong Do spearheads operational strategies, leads a high-performing team, and optimizes processes to ensure the company’s success in the Canadian market.
Mrs. Phan Dan Uyen Nguyen, a dedicated and results-oriented front-line and duty manager, brings a wealth of over 13 years of experience in the hospitality industry, demonstrating proficiency in team leadership, customer service, and operational excellence. She has worked as a Food and Beverage Attendant, Front Office Supervisor, Club Lounge Manager, VIPs & Guest Service Leader, Duty Manager, and Senior Duty Manager. As Chief Business Development Officer of NuLifeBotics, Mrs. Phan Dan Uyen Nguyen conducts comprehensive market research, formulates a robust business development strategy, and cultivates strong relationships to ensure the company’s success within the Canadian market.
The global fertility services market is on a remarkable trajectory, growing from CAD 73.79 billion in 2023 to a projected CAD 122.89 billion by 2027.
At NuLifeBotics, we cater to a diverse range of clients within the fertility industry, each with unique needs and challenges.
At NuLifeBotics, we’re not just offering a product; we’re delivering a solution that redefines fertility care.
Our AI-powered sperm analysis platform is designed to revolutionize fertility treatments by addressing the limitations of traditional methods.
Fertility care, while advanced, still faces significant challenges that impact success rates and patient experiences.
In the heart of Toronto, NuLifeBotics was born out of a shared vision to redefine the landscape of fertility care.
